Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

IBA SA : Transparence notification


Posted on: 29 Jan 18

IBA - TRANSPARENCY NOTIFICATION

Louvain-la-Neuve, Belgium, January 29, 2018, 17.35 - IBA (Ion Beam Applications SA), the world's leading provider of proton therapy solutions for the treatment of cancer, announces that it has to issue a transparency notification, in accordance with Article 14, al. 1 of the Transparency Law of May 2, 2007 on disclosure of major holdings, further to the notifications received on January 26 and 29, 2018.

Reason for the notification Upwards crossing followed by a downwards crossing of the 3% threshold further to the acquisition and disposal of shares -and thus voting rights- held as loan collateral
Persons subject to the notification requirement IBA SA, issuer
Persons that dispose of voting rights Norges Bank
Transaction date 24/01/2018   25/01/2018
Threshold that is crossed (in %) 3%
Upwards crossing further to the acquisition of voting rights
  3%
Downwards crossing further to the disposal of voting rights
Denominator 29 962 246   29 962 246
Voting rights (number) 899 685   859 382
Voting rights (%) 3,00%   2,87%
Chain of control Norges Bank is the central bank of Norway. As part of its central bank activities, Norges Bank manages Norway's foreign exchange reserves and is responsible for management of the Norwegian Government Pension Fund Global (GPFG). The formal responsibility for management of the GPFG is placed with the Ministry of Finance, but is delegated to Norges Bank. All investments are executed by Norges Bank acting as principal and all holdings are registered in the name of Norges Bank.
Additional information This notification was triggered as a result of a change in collateral.  

About IBA
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.

IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com

For further information, please contact:

IBA

Stephanie Bauwin
Legal Counsel
+32 10 203 924
Stephanie.bauwin@iba-group.com

Attachments:

http://www.globenewswire.com/NewsRoom/AttachmentNg/10727771-585e-41e9-ab89-522400bfe1f8

GlobeNewswire
globenewswire.com

Last updated on: 30/01/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.